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Abstract
Adenosine is a neuromodulator that regulates the body’s response to dopamine 
and another neurotransmitter in the brain that is responsible for motoric, emotion, 
learning, and memory function. Adenosine is a G-protein-coupled receptor and 
has four subtypes, which are A1, A2A, A2B, and A3. Adenosine A2A is located in the 
striatum of the brain. Antagonist interferes with GABA releasing, modulates acetyl-
choline and releases dopamine, and also facilitates dopamine receptor’s signaling. 
Therefore, it can reduce motoric symptoms in Parkinson’s disease. Adenosine A2A 
antagonist is also believed to have neuroprotective effects. Several compounds have 
been reported and have undergone clinical test as selective adenosine A2A antago-
nists, including istradefylline, preladenant, tozadenant, vipadenant, ST-1535, and 
SYN-115. Nonselective adenosine A2A antagonists from natural compounds are 
caffeine and theophylline.
Keywords: adenosine A2A, selective adenosine A2A antagonists, Parkinson’s disease, 
neuroprotective, natural compounds
1. Introduction
Adenosine is a neuromodulator that coordinates responses to dopamine and 
other neurotransmitters in areas of the brain responsible for motor function, mood, 
learning, and memory [1]. Adenosine consists of four receptor subtypes: A1, A2A, 
A2B, and A3 belonging to the superfamily of G-protein-coupled receptor. Adenosine 
A1 and A3 receptors are coupled to inhibitory G proteins, while A2A and A2B recep-
tors are coupled to stimulatory G proteins [2].
Adenosine A1 receptor can be found in adipose tissue, heart muscle, and inflam-
matory cells. The receptor mostly expressed by the central nervous system such 
as neocortex, cerebellum, hippocampus, and dorsal horn of the spinal cord [3]. 
The pre- and postsynaptic nerve terminals, mast cells, airway smooth muscle, and 
circulating leukocytes are the places where adenosine A2 receptor can be found. As 
the more widely dispersed receptor, adenosine A2 is divided into two receptors on 
the basis of high- and low-affinity for adenosine, A2A and A2B [4]. Striatal neurons 
are where the adenosine A2A are highly enriched; however its lower levels can also be 
found in glial cells and neurons outside the striatum [5]. The adenosine A2B recep-




Basal ganglia circuitry in normal conditions.
cells. The most widely dispersed receptor is the A3 receptor which can be found in 
the kidney, testis, lung, mast cells, eosinophils, neutrophils, heart, and the brain 
cortex [4].
Adenosine A2A receptors are found to be concentrates in GABAergic medium-
sized spiny neurons in the dopamine-rich regions of the brain. The protein trans-
lated in the adenosine A2A is carried by many other tissues such as blood vessels, 
endothelial, lymphoid cells, smooth muscle cells, and several neurons in sympa-
thetic and parasympathetic systems [6]. Therefore, the dispersion of adenosine 
A2A is not limited to the medium spiny neurons in the basal ganglia. It stimulates 
the modulation of cAMP production and increases the level of adenylyl cyclase. 
This receptor is essential in giving the medium of vasodilation of coronary arteries 
which then supports the combination of new blood vessels and giving protection 
for tissues from indirect inflammatory damage [7]. The role of the A2A in the brain 
includes influencing the activity within the indirect pathway of the basal ganglia. 
The A2A has complicated actions because it colocalizes and is physically combined 
with other unrelated G-protein-coupled receptors. Therefore, it can form heterodi-
mers such as dopamine D2/A2A, and D3/A2A, cannabinoid CB1/A2A, and glutamate 
mGluR5/A2A, as well as CB1/A2A/D2 heterotrimers [7].
The pathways which give signals used by the A2A receptor depend on the location 
of the cell and tissue, the specific G protein which couples it, and the signaling in 
the cell. The brain also carries the A2A receptor in which it plays an important role 
in regulating the glutamate and releasing the dopamine [8]. In the striatopallidal 
neurons, dopamine D2 receptors are colocalized with adenosine A2A receptors. 
Adenosine A2A receptor activity that mediates stimulation and D2 receptors that 
mediate inhibition in the striatopallidal pathway are balanced [9]. The adenosine A2A 
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likely affects motor activity by acting at different levels of the basal ganglia network. 
The basal ganglia comprise the striatum (putamen), the globus pallidus externa 
(GPe), the globus pallidus interna (GPi), substantia nigra pars compacta (SNc), 
substantia nigra reticulata (SNr), and the subthalamic nucleus (STN). The striatum 
is represented by medium-sized spiny projection neurons (MSNs), accounting 
for almost 95% of striatal neurons and using γ-aminobutyric acid (GABA) as 
neurotransmitter. The GABAergic spiny neurons give rise to the two main striatal 
efferent circuits: the striatonigral and the striatopallidal pathway. The neurons of the 
striatonigral (direct) pathway contain the neuropeptide substance P and dynorphin 
and mainly express D1 receptors; this pathway directly projects from the striatum 
to the GPi/SNr. The neurons of the striatopallidal (indirect) pathway containing the 
neuropeptide, enkephalin (ENK), predominantly express D2 receptors; this circuit 
connects the striatum with the GPi/SNr via synaptic connections in the GPe and 
STN in Figure 1. Dopamine modulates motor coordination and fine movements 
by facilitating the action of the direct pathway on stimulatory D1 receptors and by 
inhibiting indirect pathway function acting on inhibitory D2 receptors [10].
The adenosine A2A receptor has agonists and antagonists of which the roles are 
potentiating and inhibiting, respectively. The D2 receptor agonist has effects on 
motor activity, the releasing of neurotransmitter, and the expression of striatal of 
c-Fos, a factor of transcription which is used as neuronal activity’s indirect marker 
[11]. The adenosine A2A receptor has a key role in regulating the striatal dopaminer-
gic neurotransmission which produces substances that are valuable to treat neuro-
logical disorders that are relevant with dopaminergic dysfunction.
The topology of G-protein-coupled receptor is displayed in the structure of the 
adenosine A2A receptor. These receptors have a central core which consists of seven 
Figure 2. 
Crystal structure of the adenosine A2A receptor (4EIY) shown in the membrane structure. The extracellular 
and intracellular parts of the membrane are shown in red and blue beads, respectively. The disorder residues of 
intracellular loop (IL2) are modeled in dashed line.
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transmembrane helices (7TM). Each of the TM is mainly α-helical and consists of 
20–27 amino acids. Three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops connect each of the TM domain. A short helix TM8 runs 
parallel to the cytoplasmic surface of the membrane. The adenosine A2A recep-
tor has differences in length and N-terminal extracellular domain function, their 
domain of C-terminal intracellular, and their loops of intracellular/extracellular. 
These differences are shown in Figure 2.
2. The role of adenosine A2A in Parkinson’s disease
Parkinson’s disease (PD) is a chronic neurodegenerative disorder in the brain, 
marked by motoric symptoms [12]. The motoric symptoms in PD are resting 
tremor, rigidity, bradykinesia, and postural disorder. Besides motoric symptoms, 
PD also has non-motoric symptoms such as depression, hallucination, sleeping 
disorder, and decreasing cognitive and sensory functions. The main pathological 
characteristic of PD is the loss of dopaminergic neurons in substantia nigra pars 
compacta, a region in the brain that controls all the body movement and forms the 
dopamine. The development of PD also includes the formation of Lewy body, a 
deposit of cytoplasmic, eosinophilic neuronal inclusions, composed of the presyn-
aptic protein α-synuclein [13, 14].
The current therapy of PD is targeted at dopamine replacement, thereby 
decreasing the motor symptoms. It includes precursor of dopamine (levodopa), 
dopamine agonists [15, 16] monoamine oxidase type B (MAO-B) inhibitors [17], 
and catechol-O-methyltransferase (COMT) inhibitors [17, 18]. These agents 
produce undesirable side effects such as on-off effects, hallucinations, and dyskine-
sia. These effects get more severe as the treatment continued. The efficacy of these 
agents is also decreasing as the disease progressed [19].
Because of the undesirable side effects of dopamine replacement therapy, the 
non-dopaminergic therapy is continuously being explored. One of the approaches 
is selective adenosine A2A antagonist [20, 21]. Adenosine A2A receptors are found 
mainly in the striatum of rat [22, 23], which has similar distribution with the 
human brain [24, 25]. In the striatum, adenosine A2A receptors are colocalized 
with dopamine D2 receptors. These two receptors have opposite effect on motoric 
function [26]. The activation of adenosine A2A receptors will inhibit the signaling of 
dopamine D2 receptors, and conversely, the inhibition of signaling of adenosine A2A 
receptors will increase the activation of dopamine D2 receptors, therefore facilitat-
ing dopamine D2-mediated responses [11]. The inhibition of adenosine A2A recep-
tors showed motoric improvement in animal models of PD [27–30]. This also has 
desirable effect on long-term levodopa treatment such as decreasing the dyskinesia 
and increasing the therapeutic effect on levodopa [31, 32].
3. Adenosine A2A receptor antagonist as a neuroprotective
For years, adenosine-dopamine interactions have been investigated in order to 
observe their relevance for treatment of central nervous system (CNS) disorders 
[33]. It is assumed that adenosine A1 receptors (A1Rs) play an important role in 
neuroprotection as their activation at the onset of neuronal injury has shown to 
reduce brain damage in adult animal model. Vice versa, their blockade aggravates 
the damage. In other hand, adenosine A2 receptors (A2ARs) are shown to be 
upregulated in harmful brain conditions, and their blockade shows brain neuro-
protection in studied animals [34]. The blockade of A2ARs alleviates the long-term 
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burden of brain disorders in different neurodegenerative conditions, namely, 
ischemia, epilepsy, and Parkinson’s and Alzheimer’s disease, through its control 
on neuronal cell death [35].
A2ARs have been shown to be viable in serving as alternative non-dopaminergic 
strategy of Parkinson’s disease treatment because of their limited distribution in the 
striatum and the intense interaction between adenosine and dopamine receptors 
in the brain. A2ARs antagonists were shown to improve motor function in different 
animal models (primates and rodents), alone or co-administered with dopamino-
mimetic drugs, levodopa, or dopamine agonists [35]. Based on rigorous preclinical 
animal studies, istradefylline (KW6002) has shown its promising ability to increase 
motor activity in PD of the advanced stage in clinical phase IIB trial [36]. It became 
the first therapeutic agent developed to target A2ARs, and other similar compounds 
will be available in near future [37].
The recent meta-analysis (n = 6) suggested that 20 mg of istradefylline improves 
unified Parkinson’s disease ranking scale (UPDRS) III. Meanwhile at 40 mg per 
day, istradefylline could alleviate off time and motor symptoms derived from 
Parkinson’s disease [38]. Phase 3 study (613 randomized patients), done by Isaacson 
et al. concluded that greater reduction from baseline in total hours off time/day 
were shown at all-time points for istradefylline 20 and 40 mg/day, compared to 
placebo. However, future development is needed as the study has not yet reached 
statistical significance [39].
In the case of Parkinson’s disease, microglia has been suggested to be the most 
likely cell type to be targeted by A2ARs antagonists [40]. In vitro and in vivo studies 
showed that local neuroinflammation make glial cells (especially microglial cells) 
particularly sensitive to A2AR modulation [41]. Previous research done by Gao 
and Phillis is the first study to demonstrate nonselective A2AR antagonist action in 
reducing cerebral ischemic injury in the gerbil, following global forebrain ischemia 
[42]. After that, many studies have reported the neuroprotective of A2AR antago-
nists in different models of ischemia [43].
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that is indi-
cated by the progressive loss of memory and other cognitive functions, leading to 
dementia [44, 45]. Adenosine can control and integrate cognition and memory 
[46]. Both A1Rs and A2ARs, mainly located in synapses, control the release of 
neurotransmitters which are involved in memory or other cognitive processes  
[34, 47]. Methylxanthine was discovered to act as nonselective adenosine receptors 
antagonist. Caffeine, the most famous methylxanthine found in common bever-
ages, is the most widely consumed psychoactive drug. Maia and de Mendonca pre-
sented the first epidemiological data showing that the incidence of AD is inversely 
proportioned with coffee consumption [48]. Several other studies also show this 
inverse relationship [49–51]. Animal models also shown that caffeine intake may be 
beneficial for AD. In a study, a 6-month period of 0.3 g/L caffeine intake alleviated 
the cognitive deficits found in AD transgenic mice (APPsw). Furthermore, these 
mice culture neurons showed the reduced production of Aβ1–40 and Aβ1–42 peptides 
[52]. A2ARs antagonists and/or caffeine prophylactic and long-term neuroprotective 
process are suggested to be based on inhibition of reactive oxygen species activity, 
tau pathology, and Aβ production by neuronal cells [53].
A2ARs antagonist may also serve as antidepressants, as observed in animal model 
of antidepressants screening test done by El-Yacoubi et al. [54, 55]. In both tests, 
A2ARs antagonists prolong escape-directed behavior. Additionally, potential role as 
antidepressants was also observed in attenuated behavioral despairs displayed in 
both tests [55]. The relation between adenosine and depression in preclinical models 
was obtained from the genetic manipulation model of A2AR. Genetic depletion 
of A2ARs resulted in antidepressant-like phenotype in animal models [55]. The 
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A2ARs blockade also relieves stress-induced early hippocampal modifications [56]. 
However, the effect of adenosine neuromodulation system in depression is complex, 
as it has the ability to modulate several other neurotransmission systems [35].
As addressed in previous paragraphs, A2AR emerges as potential target candidate 
in various disorders. This is majorly caused by its unique interaction with D2 recep-
tors, a major psychoactive drug target. Important roles of A2AR were also observed 
in its robust neuroprotective activity, in which it mainly acts in the normalization 
of glutaminergic synapses, the control of mitochondria-induced apoptosis, and the 
control of neuroinflammation [35].
4. Current sources of the adenosine A2A antagonist
The treatment of PD currently focuses on symptom management with dopa-
minergic therapy, such as dopamine precursor L-3,4-dihydroxyphenylalanine 
(L-DOPA) (in combination with peripheral decarboxylase inhibitors) and dopa-
mine agonists [57]. Although L-DOPA is beneficial in patients with PD, with time, 
the span of the effect is shortened), the response becomes less probable, and invol-
untary muscle movements or, in a severe situation, dystonia can emerge [57]. These 
problems highlight the urgent medical need for an alternative mode of therapeutic 
intervention that can relieve the symptoms of the disorder while also allowing a 
decrease in the occurrence of side effects.
Among the non-dopaminergic therapies investigated for the treatment of PD, the 
adenosine A2A receptor antagonists show very convincingly for two main reasons: 
their selective and restricted localization in the basal ganglia circuitry and their 
interaction with dopaminergic receptors. In another word, inhibition of the interac-
tion of adenosine with the A2A receptor may provide a potential treatment for PD.
Figure 3. 
Adenosine A2A inhibitors.
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Many highly selective A2A antagonists, both xanthine and non-xanthine deriva-
tives, have been created, and some of them are being investigated as treatment for 
subjects with PD in various stage of clinical trials (Figure 3) [7, 19, 58–61]. Caffeine 
as a xanthine derivate is developed as a lead compound for the design of antagonist 
of adenosine A2A receptor [62]. Experimental model using 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism is known to be an 
evidence that caffeine have a protective effect in Parkinson’s disease [36, 63]. Some 
A2A antagonists have progressed to clinical trials by various pharmaceutical com-
panies including istradefylline [59], PBS-509, ST1535 and its metabolite ST4206, 
tozadenant, V81444, preladenant, and vipadenant [64]. Several studies of novel 
series of 2-aminoimidazo[4,5-b]pyridine-derivatives [65], arylindenopyrimidine 
[66], and bicyclic aminoquinazoline derivatives [67] as adenosine A2A antagonists 
are reported.
Various computational methods were used to study neuroprotective effect from 
adenosine A2A antagonists such as pharmacophore model [68], QSAR, molecular 
docking [69–71], and molecular dynamics [72, 73]. Orally bioavailable adenosine 
A2A receptor antagonists have been studied for its QSAR and pharmacokinetics 
properties [74].
The study of structure-kinetics relationship (SKR) is done as a complement 
to a SAR analysis at the adenosine A2A receptor. The series of 24 triazolotriazine 
derivatives showing a similar binding kinetics to the putative antagonist ZM241385 
(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)
ethyl)phenol) revealed minor affinity changes, although they varied substantially 
in their dissociation rates from the receptor [75].
5. Future direction of drug discovery of Parkinson’s disease
Various studies have been conducted in the discovery of Parkinson’s drugs 
against the target A2A receptors. The discovery of drugs assisted by computers has 
accelerated in obtaining lead compounds. Apparently, this method takes a lot of 
consideration before entering the preclinical and clinical phases. It is because this 
computational method is more able to describe the answer in preparing the next 
design. This method can also make various predictions of activities that are dif-
ficult to do in the absence of chemical compounds before they are synthesized. In 
silico prediction of various pharmacokinetic parameters and toxicity can also be 
done faster. All of these things can provide a better picture of getting a cure for 
Parkinson’s disease.
6. Conclusions
A2A receptors emerge as potential target candidate in various disorders, caused 
by its unique interaction with D2 receptors, a major psychoactive drug target. 
Various studies have been conducted in the discovery of Parkinson’s drugs against 
the target A2A receptors. In silico study brings a new approach of study with A2A 
receptors.
Acknowledgements
This work was supported by Hibah Publikasi Internasional Terindeks Untuk Tugas 
Akhir Mahasiswa UI (PITTA) 2018 by Universitas Indonesia.
Neuroprotection
8
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Widya Dwi Aryati, Nabilah Nurtika Salamah, Rezi Riadhi Syahdi  
and Arry Yanuar*
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
*Address all correspondence to: arry.yanuar@ui.ac.id
Conflict of interest
The authors declare that they have no conflict of interest or involvement with 
any organization of affiliation.
9The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.84272
References
[1] Latini S, Pedata F. Adenosine in 
the central nervous system: Release 
mechanisms and extracellular 
concentrations. Journal of 
Neurochemistry. 2008;79:463-484
[2] Stiles GL. Adenosine receptors. 
Journal of Biological Chemistry. 
1992;267:6451-6454
[3] Townsend-Nicholson A, Baker 
E, Schofield PR, Sutherland 
GR. Localization of the adenosine A1 
receptor subtype gene (ADORA1) 
to chromosome 1q32.1. Genomics. 
1995;26:423-425
[4] Livingston M, Heaney LG, Ennis 
M. Adenosine, inflammation and 
asthma? A review. Inflammation 
Research. 2004;53:171-178
[5] Boison D, Singer P, Shen H-Y, Feldon 




[6] Fredholm BB, Cunha RA, 
Svenningsson P. Pharmacology of 
adenosine A2A receptors and therapeutic 
applications. Current Topics in 
Medicinal Chemistry. 2003;3:413-426
[7] de Lera Ruiz M, Lim Y-H, Zheng 
J. Adenosine A2A receptor as a drug 
discovery target. Journal of Medicinal 
Chemistry. 2014;57:3623-3650
[8] Kull B, Svenningsson P, Fredholm 
BB. Adenosine A2A receptors are 
colocalized with and activate golf in 
rat striatum. Molecular Pharmacology. 
2000;58:771-777
[9] Torvinen M et al. Adenosine A2A 
receptor and dopamine D3 receptor 
interactions: evidence of functional A2A/
D3 heteromeric complexes. Molecular 
Pharmacology. 2005;67:400-407
[10] Schapira AHV. Present and future 
drug treatment for Parkinson’s disease. 
Journal of Neurology, Neurosurgery, 
and Psychiatry. 2005;76:1472-1478
[11] Pollack AE, Fink JS. Adenosine 
antagonists potentiate D2 dopamine-
dependent activation of Fos in the 
striatopallidal pathway. Neuroscience. 
1995;68:721-728
[12] Lozano AM, Lang AE, Hutchison 
WD, Dostrovsky JO. New developments 
in understanding the etiology of 
Parkinson’s disease and in its treatment. 
Current Opinion in Neurobiology. 
1998;8:783-790
[13] Savitt JM. Diagnosis and treatment 
of Parkinson disease: Molecules 
to medicine. Journal of Clinical 
Investigation. 2006;116:1744-1754
[14] Dauer W, Przedborski S. Parkinson’s 
disease. Neuron. 2003;39:889-909
[15] Antonini A, Tolosa E, Mizuno 
Y, Yamamoto M, Poewe WH. A 
reassessment of risks and benefits 
of dopamine agonists in Parkinson’s 
disease. Lancet Neurology. 
2009;8:929-937
[16] Yamamoto M, Schapira 
AH. Dopamine agonists in 
Parkinson’s disease. Expert Review of 
Neurotherapeutics. 2008;8:671-677
[17] Olanow CW, Stocchi F. COMT 
inhibitors in Parkinson’s disease: Can 
they prevent and/or reverse levodopa-
induced motor complications? 
Neurology. 2004;62:S72-S81
[18] Gordin A, Brooks DJ. Clinical 
pharmacology and therapeutic use 
of COMT inhibition in Parkinson’s 
disease. Journal of Neurology. 
2007;254:IV37-IV48
[19] Shook BC, Jackson PF. Adenosine 
A2A receptor antagonists and Parkinson’s 
Neuroprotection
10
disease. ACS Chemical Neuroscience. 
2011;2:555-567
[20] Schwarzschild MA, Agnati L, 
Fuxe K, Chen J-F, Morelli M. Targeting 
adenosine A2A receptors in Parkinson’s 
disease. Trends in Neurosciences. 
2006;29:647-654
[21] Salamone JD. Facing dyskinesia in 
Parkinson disease: Nondopaminergic 
approaches. Drugs Future. 2010;35:567
[22] Rosin DL, Robeva A, 
Woodard RL, Guyenet PG, Linden 
J. Immunohistochemical localization 
of adenosine A2A receptors in 
the rat central nervous system. 
Journal of Comparative Neurology. 
1998;401:163-186
[23] Fredholm BB, Svenningsson 
P. Striatal adenosine A2A receptors—
Where are they? What do they do? 
Trends in Pharmacological Sciences. 
1998;19:46-47
[24] Ishiwata K et al. First visualization 
of adenosine A2A receptors in the 
human brain by positron emission 
tomography with [11C]TMSX. Synapse. 
2005;55:133-136
[25] Svenningsson P, Hall H, Sedvall G, 
Fredholm BB. Distribution of adenosine 
receptors in the postmortem human 
brain: An extended autoradiographic 
study. Synapse. 1997;27:322-335
[26] Fink JS et al. Molecular cloning of 
the rat A2 adenosine receptor: Selective 
co-expression with D2 dopamine 
receptors in rat striatum. Molecular 
Brain Research. 1992;14:186-195
[27] Chen J-F et al. Neuroprotection by 
caffeine and A2A adenosine receptor 
inactivation in a model of Parkinson’s 
disease. Journal of Neuroscience. 
2001;21:RC143-RC143
[28] Grondin R et al. Antiparkinsonian 
effect of a new selective adenosine A2A 
receptor antagonist in MPTP-treated 
monkeys. Neurology. 1999;52:1673-1673
[29] Ongini E et al. Dual actions of A2A 
adenosine receptor antagonists on motor 
dysfunction and neurodegenerative 
processes. Drug Development Research. 
2001;52:379-386
[30] Ikeda K, Kurokawa M, Aoyama 
S, Kuwana Y. Neuroprotection by 
adenosine A2A receptor blockade in 
experimental models of Parkinson’s 
disease. Journal of Neurochemistry. 
2002;80:262-270
[31] Kanda T et al. Combined use 
of the adenosine A2A antagonist 
KW-6002 with l-DOPA or with 
selective D1 or D2 dopamine agonists 
increases antiparkinsonian activity 
but not dyskinesia in MPTP-treated 
monkeys. Experimental Neurology. 
2000;162:321-327
[32] Hauser RA, Hubble JP, Truong 
DD. Randomized trial of the adenosine 
A2A receptor antagonist istradefylline 
in advanced PD. Neurology. 
2003;61:297-303
[33] Fuxe K et al. Adenosine-dopamine 
interactions in the pathophysiology 
and treatment of CNS disorders. 
CNS Neuroscience and Therapeutics. 
2010;16:e18-e42
[34] Cunha RA. Neuroprotection by 
adenosine in the brain: From A1 receptor 
activation to A2A receptor blockade. 
Purinergic Signal. 2005;1:111-134
[35] Gomes CV, Kaster MP, Tomé 
AR, Agostinho PM, Cunha 
RA. Adenosine receptors and brain 
diseases: Neuroprotection and 
neurodegeneration. Biochimica 
et Biophysica Acta (BBA)—
Biomembranes. 2011;1808:1380-1399
[36] Kalda A, Yu L, Oztas E, Chen 
J-F. Novel neuroprotection by caffeine 
and adenosine A2A receptor antagonists 
11
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.84272
in animal models of Parkinson’s disease. 
Journal of the Neurological Sciences. 
2006;248:9-15
[37] Yamada K, Kobayashi M, Kanda 
T. Chapter Fifteen - Involvement of 
Adenosine A2A Receptors in Depression 
and Anxiety. International Review of 
Neurobiology. 2014;119:373-393. DOI: 
10.1016/B978-0-12-801022-8.00015-5
[38] Sako W, Murakami N, Motohama 
K, Izumi Y, Kaji R. The effect of 
istradefylline for Parkinson’s disease: 
A meta-analysis. Scientific Reports. 
2017;7:18018
[39] Isaacson S et al. Efficacy and 
safety of istradefylline in moderate to 
severe Parkinson’s disease: A phase 3, 
multinational, randomized, double-
blind, placebo-controlled trial (i-step 
study). Journal of the Neurological 
Sciences. 2017;381:351-352
[40] Franco R, Navarro G. Adenosine 
A2A receptor antagonists in 
neurodegenerative diseases: Huge 
potential and huge challenges. Frontiers 
in Psychiatry. 2018;9(1-5)
[41] Chen J-F, Pedata F. Modulation 
of ischemic brain injury and 
neuroinflammation by adenosine A2A 
receptors. Current Pharmaceutical 
Design. 2008;14:1490-1499
[42] Gao Y, Phillis JW. CGS 15943, An 
adenosine A2 receptor antagonist, 
reduces cerebral ischemic injury in 
the Mongolian gerbil. Life Sciences. 
1994;55:PL61-PL65
[43] Pedata F et al. Adenosine A2A 
receptors modulate acute injury 
and neuroinflammation in brain 
ischemia. Mediators of Inflammation. 
2014;805198:2014
[44] Kalaria RN et al. Alzheimer’s disease 
and vascular dementia in developing 
countries: Prevalence, management, 
and risk factors. The Lancet Neurology. 
2008;7:812-826
[45] Lesne S. Toxic oligomer species 
of amyloid-β in Alzheimer’s disease, 
a timing issue. Swiss Medical Weekly. 
2014;298:789-791
[46] Cunha RA, Agostinho PM. Chronic 
caffeine consumption prevents memory 
disturbance in different animal 
models of memory decline. Journal of 
Alzheimer's Disease. 2010;20:S95-S116
[47] Ribeiro JA, Sebastião AM, de 
Mendonça A. Adenosine receptors in 
the nervous system: Pathophysiological 
implications. Progress in Neurobiology. 
2002;68:377-392
[48] Maia L, de Mendonça A. Does 
caffeine intake protect from Alzheimer’s 
disease? Europen Journal of Neurology. 
2002;9:377-382
[49] Ritchie K et al. The neuroprotective 
effects of caffeine: A prospective 
population study (the Three City 
Study). Neurology. 2007;69:536-545
[50] Santos C, Costa J, Santos J, Vaz-
Carneiro A, Lunet N. Caffeine intake 
and dementia: systematic review and 
meta-analysis. Journal of Alzheimer's 
Disease. 2010;20:S187-S204
[51] Smith AP. Caffeine, cognitive 
failures and health in a non-working 
community sample. Human 
Psychopharmacology Clinical and 
Experimental. 2009;24:29-34
[52] Arendash GW et al. Caffeine 
protects Alzheimer’s mice against 
cognitive impairment and reduces brain 
β-amyloid production. Neuroscience. 
2006;142:941-952
[53] Marzagalli R, Castorina A. The 
seeming paradox of adenosine 
receptors as targets for the treatment 
of Alzheimer′s disease: Agonists or 
antagonists? Neural Regeneration 
Research. 2015;10:205
[54] Cantwell R, Cox JL. Psychiatric 
disorders in pregnancy and the 
Neuroprotection
12
puerperium. Current Obstetrics & 
Gynaecology. 2006;16:14-20
[55] El Yacoubi M et al. Adenosine 
A2A receptor antagonists are potential 
antidepressants: evidence based 
on pharmacology and A2A receptor 
knockout mice. British Journal of 
Pharmacology. 2001;134:68-77
[56] Cunha GMA, Canas PM, Oliveira 
CR, Cunha RA. Increased density 
and synapto-protective effect of 
adenosine A2A receptors upon sub-
chronic restraint stress. Neuroscience. 
2006;141:1775-1781
[57] Olanow CW et al. Levodopa in 
the treatment of Parkinson’s disease: 
Current controversies. Movement 
Disorders. 2004. DOI: 10.1002/
mds.20243
[58] Armentero MT et al. Past, 
present and future of A2A adenosine 
receptor antagonists in the therapy of 
Parkinson’s disease. Pharmacology & 
Therapeutics. 2011. DOI: 10.1016/j.
pharmthera.2011.07.004
[59] Jenner P. Istradefylline, a novel 
adenosine A2A receptor antagonist, 
for the treatment of Parkinson’s 
disease. Expert Opinion on 
Investigational Drugs. 2005. DOI: 
10.1517/13543784.14.6.729
[60] Pinna A. Novel investigational 
adenosine A2A receptor antagonists for 
Parkinson’s disease. Expert Opinion 
on Investigational Drugs. 2009. DOI: 
10.1517/13543780903241615
[61] Hickey P, Stacy M. Adenosine A2A 
antagonists in Parkinson’s disease: 
What’s next? Current Neurology and 
Neuroscience Reports. 2012;12:376-385
[62] Petzer JP, Petzer A. Caffeine as 
a lead compound for the design of 
therapeutic agents for the treatment of 
Parkinson’s disease. Current Medicinal 
Chemistry. 2015. DOI: 10.2174/0929867
322666141215160015
[63] Munoz DG, Fujioka S. Caffeine and 
Parkinson disease: A possible diagnostic 
and pathogenic breakthrough. 
Neurology. 2018. DOI: 10.1212/
WNL.0000000000004898
[64] Pinna A. Adenosine A2A receptor 
antagonists in Parkinson’s disease: 
Progress in clinical trials from the 
newly approved istradefylline to 
drugs in early development and those 
already discontinued. CNS Drugs. 
2014;28:455-474
[65] McGuinness BF et al. Discovery of 
2-aminoimidazopyridine adenosine 
A2A receptor antagonists. Bioorganic 
& Medicinal Chemistry Letters. 
2010;20:6845-6849
[66] Atack JR et al. JNJ-40255293, a 
novel adenosine A2A/A1 antagonist 
with efficacy in preclinical models of 
Parkinson’s disease. ACS Chemical 
Neuroscience. 2014;5:1005-1019
[67] Zhou G et al. Bioorganic & 
medicinal chemistry letters discovery of 
aminoquinazoline derivatives as human 
A2A adenosine receptor antagonists. 
Bioorganic & Medicinal Chemistry 
Letters. 2016;26:1348-1354
[68] Khanfar MA, Al-Qtaishat S, Habash 
M, Taha MO. Discovery of potent 
adenosine A2A antagonists as potential 
anti-Parkinson disease agents. Non-
linear QSAR analyses integrated with 
pharmacophore modeling. Chemico-
Biological Interactions. 2016;254:93-101
[69] Anighoro A, Bajorath J. Binding 
mode similarity measures for ranking 
of docking poses: A case study on the 
adenosine A2A receptor. Journal of 
Computer-Aided Molecular Design. 
2016. DOI: 10.1007/s10822-016-9918-z
[70] Yang X et al. A covalent antagonist 
for the human adenosine A2A receptor. 
Purinergic Signal. 2017. DOI: 10.1007/
s11302-016-9549-9
13
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.84272
[71] Jaiteh M et al. Docking screens 
for dual inhibitors of disparate drug 
targets for Parkinson’s disease. Journal 
of Medicinal Chemistry. 2018. DOI: 
10.1021/acs.jmedchem.8b00204
[72] Sabbadin D et al. Bridging 
molecular docking to membrane 
molecular dynamics to investigate 
GPCR-ligand recognition: The human 
A2A adenosine receptor as a key study. 
Journal of Chemical Information and 
Modeling. 2013. DOI: 10.1021/ci400532b
[73] Caliman AD, Swift SE, Wang Y, 
Miao Y, McCammon JA. Investigation of 
the conformational dynamics of the apo 
A2A adenosine receptor. Protein Science. 
2015. DOI: 10.1002/pro.2681
[74] Basu S et al. Design, synthesis 
of novel, potent, selective, orally 
bioavailable adenosine A2A receptor 
antagonists and their biological 
evaluation. Journal of Medicinal 
Chemistry. 2017. DOI: 10.1021/acs.
jmedchem.6b01584
[75] Guo D et al. Binding kinetics 
of ZM241385 derivatives at the 
human adenosine A2A receptor. 
ChemMedChem. 2014. DOI: 10.1002/
cmdc.201300474
